A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This is a randomized, double-blind, multicenter study to evaluate the efficacy, safety, and immunogenicity of FYB202 compared to Stelara® in patients with Moderate-to-Severe Plaque Psoriasis.
Epistemonikos ID: 15638e9383f40145fc1cf3825121d9723793f4c9
First added on: May 07, 2024